ArticlePreventive medicine reports
Human Papillomavirus Vaccine Initiation among 9-13-Year-Olds in the United States.
Article in Preventive medicine reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.Human vaccines & immunotherapeutics · 2025Pooled it
- Disparities in Healthcare Providers' Recommendation of HPV Vaccination for U.S. Adolescents: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Pooled it
- A systematic review of human papillomavirus vaccination among US adolescents.Research in nursing & health · 2021Pooled it
- Parents' uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies.BMJ open · 2018Pooled it
- Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10.Human vaccines & immunotherapeutics · 2023Trial
- Talking about recommended age or fewer doses: what motivates HPV vaccination timeliness?Human vaccines & immunotherapeutics · 2021Trial
- Provider Communication and Mothers' Willingness to Vaccinate Against Human Papillomavirus and Influenza: A Randomized Health Messaging Trial.Academic pediatrics · 2018Trial
- Article
- Review
- HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US.Human vaccines & immunotherapeutics · 2023Article
- A survey of potential acceptance of 9-valent HPV vaccine among Chinese male college students.Human vaccines & immunotherapeutics · 2023Review
- HPV vaccination coverage and factors among American Indians in Cherokee Nation.Cancer causes & control : CCC · 2023Article
- Article
- Human papillomavirus vaccinations at recommended ages: How a middle school-based educational and vaccination program increased uptake in the Rio Grande Valley.Human vaccines & immunotherapeutics · 2022Article
- Article
- Factors contributing to missed opportunities for human papillomavirus vaccination among adolescents, ages 11 to 13, in Iowa.Vaccine: X · 2022Article
- Development and Implementation of an HPV Vaccination Survey for American Indians in Cherokee Nation.International journal of environmental research and public health · 2021Article
- The role of the media on maternal confidence in provider HPV recommendation.BMC public health · 2020Article
- Patient-Level Factors Associated With Lack of Health Care Provider Recommendation for the Human Papillomavirus Vaccine Among Young Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Multi-Theory Model and Predictors of Likelihood of Accepting the Series of HPV Vaccination: A Cross-Sectional Study among Ghanaian Adolescents.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for administration among 9-26-year-old males and females, with routine vaccination recommended for 11-12-year-olds. Despite the availability of the vaccine at younger ages, few studies have explored vaccine uptake prior to age 13, and national HPV vaccination surveillance data is limited to 13-17-year-olds. Our objective was to examine rates and predictors of HPV vaccine initiation among 9-13-year-olds in the United States.
methodsA national sample of mothers of 9-13-year-olds in the United States (N=2,446) completed a 2014 Web-based survey assessing socio-demographic characteristics, child's HPV vaccination history, provider communication regarding the vaccine, and other attitudes and behaviors pertaining to vaccination and healthcare utilization. The main outcome measure was child's initiation of the HPV vaccine (i.e., receipt of one or more doses).
resultsApproximately 35% of the full sample and 27.5% of the 9-10-year-olds had initiated HPV vaccination. Females were more likely than males to have initiated HPV vaccination by the age of 13 but not by younger ages. Strength of health provider recommendation regarding HPV vaccination was a particularly salient predictor of vaccine initiation.
conclusionsApproximately a third of children may be initiating the HPV vaccine series before or during the targeted age range for routine administration of the vaccine. Because coverage remains below national targets, further research aimed at increasing vaccination during early adolescence is needed. Improving providers' communication with parents about the HPV vaccine may be one potential mechanism for increasing vaccine coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.